Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events
Authors
Collet, Jean-PhilippeMontalescot, Gilles
Agnelli, Giancarlo
Van de Werf, Frans
Gurfinkel, Enrique P.
López-Sendón, José
Laufenberg, Christopher V.
Klutman, Martin
Gowda, Neelam
Gulba, Dietrich C.
GRACE Investigators
UMass Chan Affiliations
Center for Outcomes ResearchDocument Type
Journal ArticlePublication Date
2005-11-04Keywords
Acute DiseaseAdolescent
Adult
Aged
Aged, 80 and over
Anticoagulants
Coronary Disease
Drug Therapy, Combination
Female
Hemorrhage
Heparin, Low-Molecular-Weight
Humans
Kidney Diseases
Male
Middle Aged
Platelet Glycoprotein GPIIb-IIIa Complex
Prospective Studies
Statistics as Topic
Syndrome
Treatment Outcome
Health Services Research
Metadata
Show full item recordAbstract
AIMS: To determine whether low-molecular-weight heparin (LMWH)+glycoprotein (GP) IIb/IIIa inhibitors provide greater benefit than unfractionated heparin (UFH)+GP IIb/IIIa inhibitors, irrespective of renal status. METHODS AND RESULTS: Patients in the Global Registry of Acute Coronary Events (GRACE) were divided into three groups according to creatinine clearance (CrCl): normal renal function (CrCl >60 mL/min), moderate renal dysfunction (30 CONCLUSION: In patients with renal dysfunction and non-ST-segment elevation ACS, bleeding complications are more frequent and outcomes appear worse in individuals treated with UFH compared with LMWH. Combination therapy with LMWH and GP IIb/IIIa inhibitors appears to be better tolerated than with UFH and GP IIb/IIIa inhibitors.Source
Eur Heart J. 2005 Nov;26(21):2285-93. Epub 2005 Jun 2. Link to article on publisher's siteDOI
10.1093/eurheartj/ehi337Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27244PubMed ID
15932908Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1093/eurheartj/ehi337